EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Children’s preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations

G. Hoddinott, H.R. Draper, N. Vanqa, S. Myeni, S. Staples, T. Sachs, M. Raffique, N. Tshethu, M. Palmer, L. Viljoen, K. Inabathina, R. Taneja, A.C. Hesseling, A.J. Garcia-Prats

IJTLD Open · 2025-04 · 2 (4) · 208-216

DOI: 10.5588/ijtldopen.24.0546 ↗
AbstractBibliografische Angaben

Abstract

SUMMARY BACKGROUND Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children’s preferences for more child-friendly formulations from two generic manufacturers. METHODS This was a randomised, cross-sectional ‘swish-and-spit’ taste panel study at two sites in South Africa. Each manufacturer created three flavour-blend variants for each drug. Healthy child volunteers 5–17 years old were sampled stratified by age, sex, and ethnic group and completed a preference rank-ordering and five acceptability 5-point Likert scales. We explored the blends’ acceptability using summary, comparative, and ranking statistics. RESULTS Ninety-seven and 96 children contributed data for the MFX and LZD drug blends, respectively. For both manufacturers’ MFX blends, the Friedman test showed children had a statistically significant preference for novel options over the Existing blend (Q(2) = 24,937; P < 0.001, and Q(2) = 21.213; P < 0.001, respectively). Even the most preferred MFX blend had sub-optimal acceptability, especially for one manufacturer. Children did not have a clear preference for both manufacturers’ LZD blends. These findings were not influenced by age, sex, or ethnic group. CONCLUSION Children across a broad age spectrum can provide meaningful input on the palatability preferences of TB drug formulations. Novel MFX formulation blends were recommended for development, but acceptability remains suboptimal.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →